{"product_id":"glp-x3","title":"GLP-X3 30 mg pen","description":"\u003ch2 data-section-id=\"1wupftk\" data-start=\"475\" data-end=\"488\"\u003e\u003cspan role=\"text\"\u003e\u003cstrong data-start=\"478\" data-end=\"488\"\u003eGLP-X3\u003c\/strong\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp data-start=\"490\" data-end=\"804\"\u003eGLP-X3 is a peptide positioned for controlled research settings where integrated metabolic regulation is being studied in relation to multi-receptor signaling across GLP-1, GIP, and glucagon pathways, with focus on appetite signaling, energy expenditure, and glucose homeostasis under defined metabolic conditions.\u003c\/p\u003e\n\u003chr data-start=\"806\" data-end=\"809\"\u003e\n\u003ch2 data-section-id=\"1mj5nkp\" data-start=\"811\" data-end=\"826\"\u003e\u003cspan role=\"text\"\u003e\u003cstrong data-start=\"814\" data-end=\"826\"\u003eSupports\u003c\/strong\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cul data-start=\"828\" data-end=\"1211\"\u003e\n\u003cli data-section-id=\"4ywyfp\" data-start=\"828\" data-end=\"898\"\u003eAppetite signaling and satiety response dynamics (model-dependent)\u003c\/li\u003e\n\u003cli data-section-id=\"6ugxfs\" data-start=\"899\" data-end=\"972\"\u003eMulti-receptor metabolic pathway interaction (GLP-1 \/ GIP \/ glucagon)\u003c\/li\u003e\n\u003cli data-section-id=\"1h0gzzx\" data-start=\"973\" data-end=\"1031\"\u003eEnergy expenditure and thermogenic signaling endpoints\u003c\/li\u003e\n\u003cli data-section-id=\"118lhmt\" data-start=\"1032\" data-end=\"1086\"\u003eGlucose regulation and insulin sensitivity markers\u003c\/li\u003e\n\u003cli data-section-id=\"biqwfp\" data-start=\"1087\" data-end=\"1141\"\u003eBody composition and nutrient partitioning metrics\u003c\/li\u003e\n\u003cli data-section-id=\"9ixgwn\" data-start=\"1142\" data-end=\"1211\"\u003eExposure–response relationships in multi-pathway metabolic models\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"1213\" data-end=\"1216\"\u003e\n\u003ch2 data-section-id=\"1phovsz\" data-start=\"1218\" data-end=\"1236\"\u003e\u003cspan role=\"text\"\u003e\u003cstrong data-start=\"1221\" data-end=\"1236\"\u003eDescription\u003c\/strong\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp data-start=\"1238\" data-end=\"1468\"\u003eGLP-X3 is a multi-pathway metabolic peptide associated with triple receptor signaling involving GLP-1, GIP, and glucagon pathways. These systems are central to the regulation of appetite, energy balance, and metabolic homeostasis.\u003c\/p\u003e\n\u003cp data-start=\"1470\" data-end=\"1838\"\u003eIn metabolic research, GLP-1 and GIP signaling are studied for their roles in satiety, insulin response, and nutrient handling, while glucagon-related pathways are associated with increased energy expenditure and lipid metabolism. The combined activation of these receptors enables investigation of coordinated metabolic responses rather than isolated pathway effects.\u003c\/p\u003e\n\u003cp data-start=\"1840\" data-end=\"2028\"\u003eThis compound is positioned for experimental designs focused on pathway interaction, dose–time relationships, and long-term metabolic adaptation across cellular and organism-level systems.\u003c\/p\u003e\n\u003chr data-start=\"2030\" data-end=\"2033\"\u003e\n\u003ch2 data-section-id=\"i3hq9q\" data-start=\"2035\" data-end=\"2057\"\u003e\u003cspan role=\"text\"\u003e\u003cstrong data-start=\"2038\" data-end=\"2057\"\u003eClinical Status\u003c\/strong\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp data-start=\"2059\" data-end=\"2319\"\u003eGLP-X3 is primarily explored in preclinical and early-stage research contexts examining metabolic regulation, obesity-related pathways, and glucose homeostasis. Human outcome data are still emerging and remain dependent on study design and exposure parameters.\u003c\/p\u003e\n\u003cp data-start=\"2321\" data-end=\"2335\"\u003eEvidence type:\u003c\/p\u003e\n\u003cp data-start=\"2337\" data-end=\"2416\"\u003eHuman RCT ▣ | Observational ▣ | Animal ✔ | In vitro ✔ | Regulatory approval ☐\u003c\/p\u003e\n\u003chr data-start=\"2418\" data-end=\"2421\"\u003e\n\u003ch2 data-section-id=\"evp82x\" data-start=\"2423\" data-end=\"2449\"\u003e\u003cspan role=\"text\"\u003e\u003cstrong data-start=\"2426\" data-end=\"2449\"\u003eMechanism of Action\u003c\/strong\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp data-start=\"2451\" data-end=\"2669\"\u003eGLP-X3 is associated with simultaneous activation of GLP-1, GIP, and glucagon receptor pathways, which influence metabolic signaling networks involved in appetite regulation, energy expenditure, and glucose metabolism.\u003c\/p\u003e\n\u003cp data-start=\"2671\" data-end=\"2925\"\u003eGLP-1-related signaling is studied for its role in satiety and insulin dynamics. GIP pathways contribute to nutrient handling and metabolic coordination, while glucagon receptor activation is linked to increased energy expenditure and lipid mobilization.\u003c\/p\u003e\n\u003cp data-start=\"2927\" data-end=\"3217\"\u003eThese pathways converge on intracellular signaling cascades such as cAMP-mediated regulation, mitochondrial energy utilization, and lipid oxidation processes. The combined signaling profile allows for investigation of integrated metabolic responses under controlled experimental conditions.\u003c\/p\u003e\n\u003chr data-start=\"3219\" data-end=\"3222\"\u003e\n\u003ch2 data-section-id=\"asdj0h\" data-start=\"3224\" data-end=\"3239\"\u003e\u003cspan role=\"text\"\u003e\u003cstrong data-start=\"3227\" data-end=\"3239\"\u003eBenefits\u003c\/strong\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp data-start=\"3241\" data-end=\"3591\"\u003e\u003cstrong data-start=\"3241\" data-end=\"3287\"\u003eAppetite Signaling And Satiety Regulation:\u003c\/strong\u003e\u003cbr data-start=\"3287\" data-end=\"3290\"\u003eGLP-X3 has been studied for its role in modulating appetite-related pathways through multi-receptor signaling. Activation of satiety-related systems may influence caloric intake dynamics in controlled models. This early-phase signaling is commonly tracked through behavioral and biochemical endpoints.\u003c\/p\u003e\n\u003cp data-start=\"3593\" data-end=\"3863\"\u003e\u003cstrong data-start=\"3593\" data-end=\"3641\"\u003eEnergy Expenditure And Thermogenic Response:\u003c\/strong\u003e\u003cbr data-start=\"3641\" data-end=\"3644\"\u003eGlucagon-associated signaling pathways are linked to increased thermogenic activity and fat oxidation. GLP-X3 supports the study of energy expenditure mechanisms alongside intake regulation within the same model system.\u003c\/p\u003e\n\u003cp data-start=\"3865\" data-end=\"4099\"\u003e\u003cstrong data-start=\"3865\" data-end=\"3912\"\u003eGlucose Regulation And Insulin Sensitivity:\u003c\/strong\u003e\u003cbr data-start=\"3912\" data-end=\"3915\"\u003eGLP-X3 influences pathways associated with insulin response and glucose homeostasis. Experimental models track these effects through glycemic markers and insulin sensitivity endpoints.\u003c\/p\u003e\n\u003cp data-start=\"4101\" data-end=\"4356\"\u003e\u003cstrong data-start=\"4101\" data-end=\"4149\"\u003eBody Composition And Metabolic Partitioning:\u003c\/strong\u003e\u003cbr data-start=\"4149\" data-end=\"4152\"\u003eResearch models have examined shifts in fat metabolism and nutrient utilization associated with multi-pathway activation. These effects are studied through body composition metrics and metabolic readouts.\u003c\/p\u003e\n\u003cp data-start=\"4358\" data-end=\"4568\"\u003e\u003cstrong data-start=\"4358\" data-end=\"4399\"\u003eMulti-Pathway Metabolic Coordination:\u003c\/strong\u003e\u003cbr data-start=\"4399\" data-end=\"4402\"\u003eUnlike single-pathway compounds, GLP-X3 enables investigation of coordinated signaling across multiple receptor systems, allowing for more complex metabolic modeling.\u003c\/p\u003e\n\u003cp data-start=\"4570\" data-end=\"4736\"\u003e\u003cstrong data-start=\"4570\" data-end=\"4603\"\u003eSustained Signaling Dynamics:\u003c\/strong\u003e\u003cbr data-start=\"4603\" data-end=\"4606\"\u003eMulti-receptor engagement supports longer-duration signaling studies, enabling analysis of cumulative metabolic effects over time.\u003c\/p\u003e\n\u003chr data-start=\"4738\" data-end=\"4741\"\u003e\n\u003ch2 data-section-id=\"y16vvw\" data-start=\"4743\" data-end=\"4763\"\u003e\u003cspan role=\"text\"\u003e\u003cstrong data-start=\"4746\" data-end=\"4763\"\u003eResearch Data\u003c\/strong\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"4765\" data-end=\"5254\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"4765\" data-end=\"4796\"\u003e\n\u003ctr data-start=\"4765\" data-end=\"4796\"\u003e\n\u003cth data-start=\"4765\" data-end=\"4777\" data-col-size=\"md\" class=\"\"\u003eStudy\/model\u003c\/th\u003e\n\u003cth data-start=\"4777\" data-end=\"4796\" data-col-size=\"md\" class=\"\"\u003eReported effect\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"4807\" data-end=\"5254\"\u003e\n\u003ctr data-start=\"4807\" data-end=\"4901\"\u003e\n\u003ctd data-start=\"4807\" data-end=\"4847\" data-col-size=\"md\"\u003eMulti-pathway metabolic models (animal)\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"4847\" data-end=\"4901\"\u003eCombined appetite and energy expenditure signaling\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"4902\" data-end=\"5001\"\u003e\n\u003ctd data-start=\"4902\" data-end=\"4948\" data-col-size=\"md\"\u003eObesity-related models (animal; longitudinal)\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"4948\" data-end=\"5001\"\u003eChanges in body composition and metabolic markers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5002\" data-end=\"5094\"\u003e\n\u003ctd data-start=\"5002\" data-end=\"5039\" data-col-size=\"md\"\u003eCellular receptor studies (in vitro)\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"5039\" data-end=\"5094\"\u003eActivation of multiple metabolic signaling pathways\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5095\" data-end=\"5166\"\u003e\n\u003ctd data-start=\"5095\" data-end=\"5120\" data-col-size=\"md\"\u003eEarly human observations\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"5120\" data-end=\"5166\"\u003eDose-dependent metabolic pathway responses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"5167\" data-end=\"5254\"\u003e\n\u003ctd data-start=\"5167\" data-end=\"5195\" data-col-size=\"md\"\u003eComparative pathway studies\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"5195\" data-end=\"5254\"\u003eEnhanced signaling relative to single-pathway compounds\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"5256\" data-end=\"5259\"\u003e\n\u003ch2 data-section-id=\"1jm0pp0\" data-start=\"5261\" data-end=\"5285\"\u003e\u003cspan role=\"text\"\u003e\u003cstrong data-start=\"5264\" data-end=\"5285\"\u003eStack Suggestions\u003c\/strong\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp data-start=\"5287\" data-end=\"5353\"\u003eIn extended experimental designs, GLP-X3 is sometimes paired with:\u003c\/p\u003e\n\u003cp data-start=\"5355\" data-end=\"5575\"\u003eMOTS-c → to co-study mitochondrial function and energy efficiency\u003cbr data-start=\"5420\" data-end=\"5423\"\u003eNAD+ → to examine cellular energy pathways alongside metabolic regulation\u003cbr data-start=\"5496\" data-end=\"5499\"\u003e5-Amino-1MQ → to explore NAD+ pathway interactions and metabolic signaling\u003c\/p\u003e\n\u003cp data-start=\"5577\" data-end=\"5657\"\u003eStacks discussed are for experimental design only, not safety\/efficacy guidance.\u003c\/p\u003e\n\u003chr data-start=\"5659\" data-end=\"5662\"\u003e\n\u003ch2 data-section-id=\"1h0tl47\" data-start=\"5664\" data-end=\"5692\"\u003e\u003cspan role=\"text\"\u003e\u003cstrong data-start=\"5667\" data-end=\"5692\"\u003ePossible Side Effects\u003c\/strong\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp data-start=\"5694\" data-end=\"5844\"\u003eHuman safety data for GLP-X3 are still developing and may vary depending on experimental design, exposure duration, and baseline metabolic conditions.\u003c\/p\u003e\n\u003cp data-start=\"5846\" data-end=\"6126\"\u003eExperimental considerations may include gastrointestinal response markers, glucose and insulin variability, appetite-related pathway changes, and fluid balance shifts. As with multi-pathway compounds, controlled designs may include monitoring of metabolic and signaling endpoints.\u003c\/p\u003e\n\u003chr data-start=\"6128\" data-end=\"6131\"\u003e\n\u003ch2 data-section-id=\"15frpa6\" data-start=\"6133\" data-end=\"6161\"\u003e\u003cspan role=\"text\"\u003e\u003cstrong data-start=\"6136\" data-end=\"6161\"\u003eScientific References\u003c\/strong\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp data-start=\"6163\" data-end=\"6481\"\u003eTriple agonist peptides for metabolic regulation — Review\u003cbr data-start=\"6220\" data-end=\"6223\"\u003eGLP-1 receptor signaling pathways — Review\u003cbr data-start=\"6265\" data-end=\"6268\"\u003eGIP receptor physiology and metabolic function — Review\u003cbr data-start=\"6323\" data-end=\"6326\"\u003eGlucagon receptor and energy expenditure — Review\u003cbr data-start=\"6375\" data-end=\"6378\"\u003eMulti-agonist peptide therapeutics — Review\u003cbr data-start=\"6421\" data-end=\"6424\"\u003eHormonal regulation of appetite and metabolism — Review\u003c\/p\u003e\n\u003chr data-start=\"6483\" data-end=\"6486\"\u003e\n\u003ch2 data-section-id=\"11yk4fx\" data-start=\"6488\" data-end=\"6503\"\u003e\u003cspan role=\"text\"\u003e\u003cstrong data-start=\"6491\" data-end=\"6503\"\u003eCautions\u003c\/strong\u003e\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp data-start=\"6505\" data-end=\"6791\"\u003eFor educational and scientific context only; not intended to diagnose, treat, cure, or prevent any disease.\u003cbr data-start=\"6612\" data-end=\"6615\"\u003eUse only in controlled research environments under qualified supervision.\u003cbr data-start=\"6688\" data-end=\"6691\"\u003eDiscontinue experimental use if adverse responses are observed.\u003c\/p\u003e","brand":"Peptoora ","offers":[{"title":"30 mg","offer_id":61580695241034,"sku":null,"price":529.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0887\/1139\/7706\/files\/GLP-X3_12mg.png?v=1775898775","url":"https:\/\/peptoora.com\/products\/glp-x3","provider":"Peptoora LTD","version":"1.0","type":"link"}